New drug SUL-238 aims to boost brain energy in Parkinson's patients
NCT ID NCT07322887
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tests a new drug called SUL-238 in people with early, untreated Parkinson's disease. The goal is to see if the drug improves how brain cells produce energy, measured with a special MRI scan. Participants will take the drug or a placebo daily for 28 days and have regular checkups. The study involves 45 adults and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CTC Netherlands BV
RECRUITINGGroningen, 9713 GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.